Are There New Treatments for Treatment-Resistant LPP?

When standard treatments for lichen planopilaris (LPP) have not worked, there are newer therapies, off-label medications, and clinical trials currently being studied that you can discuss with a hair loss specialist. Navigating permanent hair loss is emotionally taxing, and it is natural to look for new solutions. While evidence for emerging options is still limited and many are considered preliminary, some approaches have shown promise in reducing active inflammation.

It is important to set realistic expectations: the medical goal of these treatments is to stabilize the condition and stop further scarring, as follicles that have already been destroyed by LPP cannot be restored. Discussing your exact diagnosis, past treatments, and personal risk tolerance with your doctor is the best way to determine if an emerging therapy or clinical trial is a safe and appropriate next step for you.

Understanding Clinical Trials and Active Disease

Researchers are actively testing new approaches for LPP through clinical trials. Before exploring trials or experimental therapies, your dermatologist will evaluate whether you have active inflammation (the immune system is currently attacking follicles) rather than just permanent scarring.

Assessing Disease Activity: Doctors typically look for signs of active disease through symptoms (itching, burning), a scalp examination, a “hair pull” test, and trichoscopy (using a special magnifier to look at the scalp). While a scalp biopsy can help confirm LPP or rule out other conditions, it is not always mandatory for diagnosis, and trial requirements vary ^[1][2].

What Joining a Trial Involves: Clinical trials are experiments to see if a treatment is safe and effective. Depending on the trial’s phase and design, participation may involve:

• Randomization and Placebos: You might be randomly assigned to receive a placebo (an inactive substance) rather than the active drug.
• Washout Periods: Trials often require you to stop your current treatments for a specific period before starting the study ^[2][3]. Never stop or taper your current treatments independently to try to qualify for a trial; doing so can cause your disease to flare.
• Commitment: Trials usually require extra clinic visits, blood draws, standardized photographs, and sometimes scalp biopsies.
• Rights: You always have the right to withdraw from a clinical trial at any time.

JAK Inhibitors: An Emerging Approach

The most discussed emerging class of medications for LPP are JAK inhibitors (Janus kinase inhibitors), which work by blocking specific inflammatory pathways. These medications are off-label (approved by the FDA for other diseases, but not specifically for LPP, meaning insurance coverage and monitoring may differ).

• Tofacitinib: A retrospective study (looking back at past patient records) of 74 adults with treatment-resistant LPP found that oral tofacitinib significantly reduced disease activity ^[4]. However, in a 37-person randomized trial (the gold standard of studies), tofacitinib improved some clinical signs but did not significantly outperform a placebo in lowering the overall LPP Activity Index (a standardized score used to measure disease severity) ^[5].
• Brepocitinib: A small 52-week Phase 2a trial (an early-stage trial testing basic safety and preliminary efficacy) involving patients with scarring alopecias found improvements in clinical severity and markers of inflammation ^[6].

Serious Safety Risks and Monitoring: It is crucial to understand that JAK inhibitors carry serious, potentially life-threatening risks. Regulatory agencies have issued warnings for some JAK inhibitors regarding increased risks of serious or opportunistic infections (like tuberculosis or shingles), major cardiovascular events (like heart attacks), blood clots, and certain cancers. These risks vary depending on the specific drug and your personal factors, such as age, smoking history, and history of cardiovascular disease or blood clots.
Taking a JAK inhibitor requires a strict safety plan ^[4]. This is not just “regular blood tests”; it involves baseline screening for tuberculosis and hepatitis, vaccination planning, and ongoing monitoring of liver function, kidney function, blood counts, and cholesterol (lipids) ^[4].

Seek urgent medical advice for serious infection symptoms, chest pain, shortness of breath, or a painful swollen leg if taking these medications.

Other Off-Label Systemic Medications

If standard therapies fail, a specialist may suggest other off-label immune-modulating medications. There is no universally agreed-upon sequence for these drugs; they are highly individualized based on your health profile.

Note: Never start, stop, or adjust immune-modulating medications without direct supervision from your doctor.

Biologics and Procedural Therapies

• Biologics: Medications targeting specific immune proteins (like IL-17 and IL-23 inhibitors) have been used in isolated case reports for LPP ^[11][12]. A case report is the lowest level of evidence; these drugs are not established therapies for LPP and require much more research ^[13].
• Procedural Treatments: Platelet-rich plasma (PRP) and low-level light therapy have been explored in small studies ^[14][3]. While they may help improve symptoms or provide slight cosmetic density improvements, it is not established that they control the underlying follicular inflammation of LPP ^[14]. They can be costly out-of-pocket and should not replace proven anti-inflammatory medical treatments.